Description

NSE notifies the listing of equity shares of Sai Parenterals Limited on the Capital Market segment effective April 02, 2026, with an issue price of Rs. 392 per share and 44,179,231 shares admitted to dealings.

Summary

NSE has notified the listing of equity shares of Sai Parenterals Limited (symbol: SAIPARENT) on the Capital Market segment effective April 02, 2026. The IPO was issued at Rs. 392 per share with a face value of Rs. 5 per share. A total of 44,179,231 equity shares have been admitted to dealings, with the security assigned ISIN INE0H9F01037.

Key Points

  • Symbol: SAIPARENT, Series: EQ, ISIN: INE0H9F01037
  • Issue price: Rs. 392 per share; Face value: Rs. 5 per share
  • Total shares listed: 44,179,231
  • Market lot size: 1 share
  • Effective date: April 02, 2026
  • Security will participate in the pre-open session for IPO and Other category scrips per SEBI circular CIR/MRD/DP/01/2012 & CIR/MRD/DP/02/2012 dated January 20, 2012
  • Registrar: Bigshare Services Private Limited, Mumbai

Regulatory Changes

No new regulatory changes introduced. Listing is governed by Regulation 3.1.1 and Regulation 2.5.5 of the National Stock Exchange (Capital Market) Trading Regulations Part A.

Compliance Requirements

  • Members must identify the security only by its designated codes (SAIPARENT/EQ) for trading purposes
  • Trading must be conducted in the specified lot size of 1 share
  • Members should note the security’s inclusion in the pre-open IPO session category

Important Dates

  • Circular date: April 01, 2026
  • Effective listing date: April 02, 2026
  • Lock-in expiry dates vary by tranche:
    • April 28, 2026 (778,112 shares)
    • June 27, 2026 (1,564,242 shares)
    • October 01, 2026 (multiple tranches totalling ~17M shares)
    • April 01, 2027 (214,280 shares)
    • October 01, 2027 (multiple tranches totalling ~11M shares)
    • Free (no lock-in): ~14.7M shares
  • Financial year: April 2026 – March 2027

Impact Assessment

The listing of Sai Parenterals Limited introduces a new pharmaceutical/parenteral drug manufacturer to the NSE Capital Market segment. With 44.18 million shares at an issue price of Rs. 392, the implied market capitalisation at listing is approximately Rs. 17.3 billion. A significant portion of shares are subject to lock-in restrictions through October 2027, limiting near-term float. Retail and institutional investors who received IPO allotments may trade freely from April 02, 2026, subject to lock-in schedules applicable to promoter and anchor tranches.

Impact Justification

Standard IPO listing notification for a mid-sized pharmaceutical company; relevant to investors in Sai Parenterals Limited but limited broader market impact.